UroGen Pharma Ltd.
URGN
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase IIIā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$23.24
Price-1.28%
-$0.30
1Y
Price
Market Cap
$1.075b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-171.2%
EBITDA Margin-206.2%
Net Profit Margin-165.0%
Free Cash Flow MarginRevenue
$94.238m
+4.3%
1y CAGR+14.0%
3y CAGR+19.0%
5y CAGREarnings
-$154.968m
-22.1%
1y CAGR-13.1%
3y CAGR-9.6%
5y CAGREPS
-$3.32
-12.2%
1y CAGR+10.1%
3y CAGR+8.5%
5y CAGRBook Value
-$93.376m
$208.717m
Assets$302.093m
Liabilities$125.921m
DebtDebt to Assets
60.3%
-1.1x
Debt to EBITDAFree Cash Flow
-$123.528m
-27.3%
1y CAGR-13.7%
3y CAGR-10.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company